Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol

NCT06413433 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

450

Enrollment

INDUSTRY

Sponsor class

Conditions

Binge-Eating Disorder

Interventions

DRUG: Solriamfetol 150 mg
DRUG: Solriamfetol 300 mg
DRUG: Placebo

Sponsor

Axsome Therapeutics, Inc.